[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bloodstream-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bloodstream-infections":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,82,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100647883","infections-in-patients-treated-with-car-t-100647883",false,"NCT07713511","INfections in Patients Treated With CAR-T","INfections in Patients Treated With CAR-T: Analysis of Incidence, Risk Factors, and Management Strategies","IN-CART","Inclusion Criteria:\n\n* Diagnosis of relapsed\u002Frefractory multiple myeloma or B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), high-grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL)\n* Receipt of CAR-T infusion at IRCCS AOUBo\n* Age ≥18 years at the time of CAR-T infusion\n* Signed informed consent\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":20,"type":21},290,"ESTIMATED","OBSERVATIONAL","This study includes adults with multiple myeloma or B-cell lymphoma who were\u002Fwill be treated with CAR-T cell therapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna. The aim is to better understand infections that may occur during the first year after CAR-T treatment, including how often they happen, their causes, and factors that may increase the risk. The study will use information from patients treated in the past and from newly enrolled patients. For some patients who develop fever after CAR-T therapy, a rapid molecular blood test will be used alongside standard tests to help identify bloodstream infections more quickly and support timely clinical care.",[25,26,27,28,29],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma","B-Cell Non-Hodgkin Lymphoma","Bloodstream Infections","CAR-T Cell Therapy",[31,32,29,33,34,35,36,37,38,39],"Multiple Myeloma","B-cell Non-Hodgkin Lymphoma","CAR-T Cell Infusion","Bloodstream Infection","Infectious Complications","CAR-T","ddPCR blood test","Cytokine Release Syndrome","CRS","NOT_YET_RECRUITING","2026-07-17",{"date":43,"type":44},"2026-07-20","ACTUAL",{"date":46,"type":21},"2026-11-01",{"date":48,"type":21},"2029-04-30",{"name":50,"class":51},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":63,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":52},"100548211","infectious-disease-registry-biobank-100548211","NCT06418048","INfectious DIsease REgistry BIObank","Prospective Registry and Biobank of Patients With Infectious Diseases","INDI-REBIO","Inclusion Criteria:\n\n* Patients with clinically suspected or microbiologically documented infectious diseases (bacterial, viral, fungal or parasitic);\n* At least 18 years of age or older;\n* Able to provide informed consent;\n* Participants who are unable to understand the study protocol or are unable to give informed consent, but have a legal representative\n\nExclusion Criteria:\n\n\\- Participants who are unable to understand the study protocol or are unable to give informed consent, and have no legal representative.",{"count":62,"type":21},10000,"20 Years","Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.",[28,66,67,68,69,70,71],"Central Nervous System Infections","Bone and Joint Infections","Endovascular Infections","Infective Endocarditis","CIED-related Infections","Vertebral Osteomyelitis","RECRUITING","2026-04-15",{"date":75,"type":44},"2026-04-20",{"date":77,"type":44},"2024-02-01",{"date":79,"type":21},"2044-07-31",{"name":81,"class":51},"IRCCS San Raffaele",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":22,"phases":4,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":52},"100624354","clinical-efectiveness-of-a-multiplex-pcr-based-rapid-diagnostic-method-in-bloodstream-infections-100624354","NCT07408544","Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections","Evaluation of the Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections: A Prospective Randomized Controlled Study","CEMP-RDI","Inclusion Criteria:\n\n* Age 18 years or older\n* Clinical suspicion of bloodstream infection\n* Positive blood culture signal\n* Patients managed in hospital wards or intensive care units\n* Ability to provide informed consent (patient or legally authorized representative)\n\nExclusion Criteria:\n\n* Recurrent episode of the same bloodstream infection\n* Inadequate or insufficient blood culture sample for analysis\n* Refusal or inability to provide informed consent\n* Death within the first 24 hours after blood culture collection\n* Loss to follow-up during the study period",{"count":91,"type":21},300,"4 Weeks","Bloodstream infections (BSIs) are associated with high morbidity and mortality, and delays in initiating appropriate antimicrobial therapy significantly worsen clinical outcomes. Conventional culture-based microbiological methods require 24-72 hours to provide definitive pathogen identification and antimicrobial susceptibility results, often leading to prolonged use of broad-spectrum empirical therapy. Rapid multiplex PCR-based diagnostic tests have the potential to shorten diagnostic timelines by identifying pathogens and resistance genes within approximately one hour; however, data on their real-world clinical impact remain limited.\n\nThis prospective, randomized, controlled, single-center study aims to evaluate the clinical effectiveness and diagnostic performance of a multiplex PCR-based rapid diagnostic method applied directly to positive blood culture bottles in adult patients with bloodstream infections. A total of 300 patients (≥18 years) with positive blood culture signals will be randomized 1:1 to either a study group or a control group. In the study group, positive blood cultures will be analyzed using both standard microbiological methods and a multiplex PCR panel, while the control group will undergo standard microbiological diagnostics alone.\n\nThe primary endpoint is time to optimal antimicrobial therapy (OTT), defined as the time from blood culture collection to initiation of the narrowest-spectrum, guideline-recommended antimicrobial agent active against the identified pathogen. Secondary endpoints include time to effective antimicrobial therapy (ETT), time to pathogen identification, antimicrobial escalation or de-escalation rates, length of hospital stay, total duration of antimicrobial therapy, and 28-day all-cause mortality.\n\nClinical, demographic, and microbiological data will be collected prospectively, including comorbidity indices and severity scores. Randomization will be stratified by ICU versus ward admission, presence of neutropenia, and Charlson Comorbidity Index to ensure balanced groups. Diagnostic accuracy of the multiplex PCR panel will be assessed by calculating sensitivity, specificity, predictive values, and agreement with standard culture methods.\n\nThis study seeks to determine whether rapid multiplex PCR diagnostics can meaningfully improve antimicrobial stewardship and clinical outcomes in patients with bloodstream infections compared with conventional diagnostic workflows.",[28,95,96],"Bacteremia and Sepsis","Fungemia",[34,98,99,100,101],"Rapid Diagnostic Test","Multiplex PCR","Molecular Diagnostics","Time to Optimal Therapy","2026-02-12",{"date":104,"type":44},"2026-02-13",{"date":106,"type":44},"2026-01-01",{"date":108,"type":21},"2027-01-01",{"name":110,"class":51},"Istanbul Medipol University Hospital",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":119,"studyType":22,"phases":4,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":52},"100576945","blood-ddpcr-for-early-identification-and-dynamic-surveillance-of-pathogenic-bacteria-in-icu-septic-patients-a-single-centre-prospective-observational-study-100576945","NCT06791889","Blood DdPCR for Early Identification and Dynamic Surveillance of Pathogenic Bacteria in ICU Septic Patients: a Single-centre, Prospective, Observational Study","Inclusion Criteria:\n\n* Patients with first diagnosis of sepsis after ICU admission\n\nExclusion Criteria:\n\n* Age under 18 years\n* Do not meet Sepsis 3.0 diagnostic criteria\n* Refusal to sign informed consent",{"count":118,"type":21},60,"1 Month","The purpose of this study is to investigate the efficacy of droplet digital PCR (ddPCR) in identifying pathogenic organisms in ICU sepsis patients, aiming to find a method that allows early identification of pathogenic organisms and dynamic surveillance in order to assess the association between pathogenic species and loads and clinical characteristics and outcomes.",[122,28,123],"Sepsis","Critically Ill Intensive Care Unit Patients",[125,122,126],"ddPCR","ICU","2025-03-12",{"date":129,"type":44},"2025-03-17",{"date":131,"type":44},"2024-09-15",{"date":133,"type":21},"2025-12-31",{"name":135,"class":51},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"]